OriGene Technologies, Inc., is a gene centric life sciences company dedicated to the support of academic, pharmaceutical and biotech companies in their research of gene functions and drug discovery. OriGene develops proteins, antibodies, and other molecular tools to allow researchers to analyze their data on a multiplex level. OriGene's novel product lines include the world's largest cDNA and shRNA clone collections, over 5,000 purified human proteins, high quality monoclonal antibodies (TrueMAB™), 140,000 highly validated human tissues, and protein microarray products and services. OriGene also provides a broad range of antibody validation products including genome-wide tagged antigen standards and extensive IHC slides derived from the Company's tissue collection. Through its recent acquisition of Blue Heron Biotechnology, a pioneer in the gene synthesis business, OriGene provides a whole product solution for customers within the life science community. On March 12, 2012, OriGene Technologies, Inc. announces the acquisition of Beijing Zhongshan Golden Bridge Biotechnology Co., Ltd (ZsBio). The strategic acquisition establishes OriGene's leading position in the Chinese pathology testing market.